Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventors Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Technologies
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • Core activities
          • Stories and insights
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Technologies
        • Go back
        • Overview
        • Innovation against cancer
        • Assistive robotics
        • Space technologies
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
          • Go back
          • Overview
          • Publications
        • Research universities and public research organisations
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2024
          • Go back
          • Overview
          • Executive summary
          • Driver 1 – People
          • Driver 2 – Technologies
          • Driver 3 – High-quality, timely products and services
          • Driver 4 – Partnerships
          • Driver 5 – Financial Sustainability
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1589/19 (Competing antibodies/IMMUNEX) 10-03-2022
Facebook X Linkedin Email

T 1589/19 (Competing antibodies/IMMUNEX) 10-03-2022

European Case Law Identifier
ECLI:EP:BA:2022:T158919.20220310
Date of decision
10 March 2022
Case number
T 1589/19
Petition for review of
-
Application number
15168899.1
IPC class
C07K 16/28
A61P 19/02
A61P 31/04
C07K 14/715
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 428.2 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Use of interleukin-4 receptor antibodies and compositions thereof

Applicant name
Immunex Corporation
Opponent name

Regeneron Pharmaceuticals, Inc.

Sanofi

Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 76(1)
European Patent Convention Art 84
Rules of procedure of the Boards of Appeal Art 13(2)
Rules of procedure of the Boards of Appeal Art 12(1)(a)
Keywords

Divisional application - subject-matter extends beyond content of earlier application

Divisional application - main request and auxiliary request 1 (yes)

Clarity - auxiliary requests 2 and 3 (no)

Basis of proceedings - decision under appeal

Catchword
-
Cited decisions
G 0001/06
G 0003/14
Citing decisions
-

I. The patent proprietor (appellant) filed an appeal against the decision of the opposition division to revoke European patent No. 2 990 420, entitled "Use of interleukin-4 receptor antibodies and compositions thereof". The patent was granted on European patent application No. 15 168 899.1, a divisional application of European patent application No. 10 185 626.8, in turn a divisional application of European patent application No. 01 952 133.5. The latter had been filed as an international application published as WO 01/92340 ("earlier application as filed").

II. Two oppositions had been filed against the granted patent. The opposition proceedings were based on the grounds under Article 100(a) EPC, lack of novelty (Article 54 EPC) and lack of inventive step (Article 56 EPC), as well as the grounds under Article 100(b) and (c) EPC.

III. The decision under appeal dealt with sets of claims of a main request and of auxiliary requests 1 to 3, all filed with the letter dated 6 March 2018. As concerns the main request, the opposition division held that the claims were clear (Article 84 EPC) and did not relate to subject-matter extending beyond the content of the application as filed (Article 123(2) EPC) and of the earlier application as filed (Article 76(1) EPC). However, the invention defined in the claims was not sufficiently disclosed (Article 83 EPC). The conclusions relating to Article 83 EPC applied equally to the sets of claims of auxiliary requests 1 to 3.

IV. With the statement setting out the grounds of appeal, the appellant filed four documents in relation to issues that the board ultimately did not decide on in this appeal. Accordingly these documents are not addressed further in this decision. The appellant also filed arguments to the effect that the invention defined in the claims of each of the requests considered by the opposition division was sufficiently disclosed.

V. Both opponents submitted replies to the appeal, including arguments inter alia to the effect that the claims were not clear (Article 84 EPC) and related to subject-matter extending beyond the content of the earlier application as filed (Article 76(1) EPC). Opponent 1 (respondent I) filed three further documents and opponent 2 (respondent II) filed two further documents.

VI. The board summoned the parties to oral proceedings in line with the parties' requests.

VII. Respondents I and II each made a further written submission on the merits of the case.

VIII. In a subsequent communication under Article 15(1) RPBA 2020, the board informed the parties of its preliminary opinion on various matters concerning the appeal, inter alia that claim 1 of the main request and auxiliary request 1 related to subject-matter extending beyond the content of the earlier application as filed and claim 1 of auxiliary requests 2 and 3 lacked clarity.

IX. At the end of the oral proceedings the chair announced the board's decision.

X. The sets of claims of the main request and auxiliary requests 1 to 3 are identical to those considered by the opposition division. Claim 1 of each request reads as follows.

Claim 1 of the main request reads:

"1. A fully human monoclonal antibody capable of inhibiting an IL-4 induced biological activity and capable of inhibiting an IL-13-induced biological activity that competes with a fully human reference IgM antibody for binding to a cell that expresses human IL-4 receptor (IL-4R), wherein:

a) the light chain of the reference IgM antibody is a kappa light chain and the variable region sequence of the light chain is the sequence of SEQ ID NO:6 and the variable region sequence of the heavy chain of the reference IgM antibody is the sequence of SEQ ID NO:8; or

b) the light chain of the reference IgM antibody is a kappa light chain and the variable region sequence of the light chain is the sequence of SEQ ID NO:26 and the variable region sequence of the heavy chain of the reference IgM antibody is the sequence of SEQ ID NO:24."

Claim 1 of auxiliary request 1 reads (differences relative to claim 1 of the main request highlighted by the board):

"1. A fully human monoclonal antibody capable of inhibiting an IL-4 induced biological activity and capable of inhibiting an IL-13-induced biological activity that competes with a fully human [deleted: reference] IgM antibody for binding to a cell that expresses human IL-4 receptor (IL-4R) for use in a method of treating dermatitis, atopic dermatitis, contact dermatitis, or asthma, wherein:

a) the light chain of the [deleted: reference] IgM antibody is a kappa light chain and the variable region sequence of the light chain is the sequence of SEQ ID NO:6 and the variable region sequence of the heavy chain of the [deleted: reference] IgM antibody is the sequence of SEQ ID NO:8; or

b) the light chain of the [deleted: reference] IgM antibody is a kappa light chain and the variable region sequence of the light chain is the sequence of SEQ ID NO:26 and the variable region sequence of the heavy chain of the [deleted: reference] IgM antibody is the sequence of SEQ ID NO:24."

Claim 1 of auxiliary request 2 and claim 1 of auxiliary request 3 read as claim 1 of the main request and claim 1 of auxiliary request 1, respectively, except that they comprise the additional wording at the end of alternative a)

"[...] and wherein the reference IgM antibody is generated in transgenic mouse strain ((CMD)++; (JKD)++; (HCo7)11952+/++; (KCo5)9272+/++)."

and they no longer include alternative b). Additionally, in the case of auxiliary request 3, the term "reference" is not present in this additional wording.

XI. The following documents are referred to in this decision:

D116: Declaration Sir Evans (13 December 2018)

D117: Declaration Prof. Oettinger (13 December 2018)

D131: US 5,770,429

D132: Declaration Prof. DeFranco (10 December 2018)

D154: Declaration Dr. King (6 February 2019)

XII. The appellant's arguments relevant to this decision may be summarised as follows:

Main request and auxiliary request 1 - claim 1

Extension beyond the content of the earlier application as filed (Article 76(1) EPC)

Admittance of submissions by the appellant at the oral proceedings (Article 13(2) RPBA 2020)

The submissions at the oral proceedings were not new to the respondents since they had been presented throughout the opposition proceedings, as reflected in the decision under appeal.

The definition of the reference antibody

The claim recited the features IgM, kappa light chain and SEQ ID numbers 6 and 8, or 26 and 24, for the variable light and heavy chains, and thus defined the reference antibody with the same level of characterising detail as provided in the earlier application.

Antibody 6-2 was characterised in the earlier application as filed by the sequence of its variable regions, i.e. SEQ ID NOs: 6 and 8. It was not characterised by its whole sequence (see page 24, lines 6 to 9, 21 to 23 and 35 to 39). The same applied to antibody 1B7 (see page 28, line 29 onwards and page 29, line 8).

The kappa light chain was disclosed in figure 4 in combination with page 2, last two lines.

Article 76(1) EPC did not require any additional characterisation which was not present in the earlier application as filed to be provided in the claim.

As stated in the Guidelines for Examination at the EPO, G-II, 5.6.1.1., a claim defining an antibody structurally by the three CDRs of its light and heavy chains was clear.

The wording "particular antibody" and "examples", used in the same sentence as antibody 2-6, on page 24, lines 21 and 16, did not mean a "specific" antibody. Likewise the reference to a clone, in example 6, did not define a specific antibody either since the clone had not been characterised in the earlier application in any further detail.

Mention of derivatives, on page 25 and page 30, referred to alternative antibodies and was not to be confused with the reference antibody in the claim.

Auxiliary requests 2 and 3 - claim 1

Clarity (Article 84 EPC)

The expression "transgenic mouse strain ((CMD)++; (JKD)++; (HCo7)11952+/++; (KCo5)9272+/++)" used standard terminology, as explained in document D154 (see pages 4 to 6). Thus, the claim was clear.

As regards the meaning and sequence of the transgenes HCo7 and KCo5, reference was made to the patent in paragraphs [0246] and [0247] and the reference therein to document D131 (document D131 corresponded to the patent document cited in the patent in paragraph [0246], penultimate line). Document D131 disclosed the terms HCo7 and and KCo5 and referred to a library of genomic DNA (see examples 21, 37 and 38). Reference was made in this context to document D154, which furthermore included a list of publications showing that the deletion of genes, represented by "CMD" and "JKD", was known in the state of the art.

In sum, the expression would have been understood by the skilled person.

XIII. The respondents' arguments relevant to this decision may be summarised as follows:

Main request and auxiliary request 1 - claim 1

Extension beyond the content of the earlier application as filed (Article 76(1) EPC)

Admittance of submissions by the appellant at the oral proceedings (Article 13(2) RPBA 2020)

In accordance with the RPBA, the parties should present their complete case as early as possible. However, up until the oral proceedings, the appellant had not presented its case on the relevant points and consequently any submissions that would result in a change of the board's preliminary opinion should not be admitted into the appeal proceedings (Article 13(2) RPBA 2020). No exceptional circumstances had been advanced.

It was established case law of the boards of appeal that submissions made before the opposition division were not automatically part of the appeal proceedings, even when there was an explicit reference to those submissions in a letter (see Case Law of the Boards of Appeal of the EPO, 9th edition 2019 (hereinafter CLBA), pages 1173 to 1174).

Definition of the reference antibody

The "gold standard" required that subject-matter disclosed in a divisional application was directly and unambiguously derivable from the earlier application as filed and did not allow for any doubts that new technical matter was present.

The designations "6-2" and "1B7" in the earlier application related to specific antibodies (page 24, line 21 referring to "particular" antibodies and line 16, referring to "examples" of antibodies). However, the claims referred to only some of their characteristics when defining the reference antibody.

Also the examples in the earlier application disclosed that these designations related to specific antibodies since 6-2, for example, also designated a specific hybridoma clone (see example 6, page 46, lines 31 to 35, and example 4). The same applied to antibody and clone 1B7 (see example 9).

Furthermore, the earlier application did mention the heavy chains of the antibodies, stating "The amino acid sequence of the heavy chain of MAb 1B7 is identical to that of MAb 63" (see page 29, lines 3 to 5) and disclosed that derivates could be prepared from the specific antibodies (see page 30, lines 3 to 5 and 8).

Thus, the description of the earlier application provided more detailed information on the reference antibodies than that present in the claim, which provided a generalised definition of the specific antibodies with the internal designations "6-2" and "1B7". The amendment contravened the requirements of Article 76(1) EPC.

Moreover, the disclosure of the kappa light chain, in figure 4, referred merely to the variable domain instead of referring to the light chain as a whole. Thus, also this feature in the claim was not disclosed in the earlier application as filed.

Auxiliary requests 2 and 3 - claim 1

Clarity (Article 84 EPC)

The claim was not clear because, by reference being made to the transgenic mouse strain, the antibody was defined in product-by-process terms.

Moreover, a claim should be clear on its own. In particular the meaning of an essential feature, as was the case here, needed to be clear from the wording of the claim alone (see opinion G 1/04 of the Enlarged Board of Appeal and CLBA, page 290). However, the skilled person was not able to determine the sequences of the transgenes, for three main reasons: (i) the terminology used to define the transgenic mouse strain was not standard in the field; (ii) even when using the description to interpret this feature, there were discrepancies as to the transgene corresponding to the kappa light chain, as to the meaning of the symbol "++" and as to the meaning of the symbol "+/++"; and (iii) even when consulting the references cited in the description, the sequences for the transgenes KCo5 and HCo7 were not retrievable.

As regards (i), all the publications cited in the description originated from a single research group and consequently could not demonstrate that the meaning of the terminology in the claim was standard in the field. The authors of documents D116, D117 and D132 stated that the terminology was not standard in the field. As for document D154, it was apparent it could not have the same probatory value as documents D116, D117 and D132 since it was authored by an employee of the appellant.

As regards (iii), the reference in the patent to Chen et al., in the context of JKD, could not be retrieved. The sequence of transgene HCo7 was not known even when taking into account the reference in the patent to document D131. The only information disclosed in this document about a sequence HCo7 was that it was derived from an anonymous phage library. It was therefore not possible to retrieve the sequence (see documents D116 and D117). Also, the sequence was not clear for the constant region designated by KCo5 (see document D116, paragraph 23).

XIV. The appellant's requests relevant to the decision were that the decision under appeal be set aside and that the case be remitted to the opposition division for consideration of outstanding grounds for opposition, namely novelty and inventive step, in relation to the sets of claims of the main request and of auxiliary requests 1 to 3, all filed with the letter dated 6 March 2018.

Respondent I's request relevant to the decision was that the appeal be dismissed.

Respondent II's requests relevant to the decision were that the appeal be dismissed and that, should the board set aside the decision under appeal, the case be remitted to the opposition division for consideration of the outstanding grounds for opposition.

1. The appeal complies with the requirements of Articles 106 to 108 EPC and the further provisions referred to in Rule 101(1) EPC and is admissible.

Main request and auxiliary request 1 - claim 1

Extension beyond the content of the earlier application as filed (Article 76(1) EPC)

Admittance of submissions by the appellant at the oral proceedings (Article 13(2) RPBA 2020)

2. The respondents requested that new submissions by the appellant, made in the context of Article 76(1) EPC at the oral proceedings, not be admitted into the proceedings under Article 13(2) RPBA 2020, applicable to the present appeal case pursuant to Articles 24 and 25 RPBA 2020.

3. The board notes that the appellant's submissions did not go beyond the reasoning provided by the opposition division in its decision (see decision under appeal point 1.2.4, second paragraph). The decision under appeal is part of the appeal proceedings, as confirmed in Article 12(1)(a) RPBA 2020. Thus, the board concludes that no new submissions were presented.

Definition of the reference antibody

4. Article 76(1), second sentence, EPC provides that a European divisional application may be filed only in respect of subject-matter which does not extend beyond the content of the earlier application as filed. According to decision G 1/06 of the Enlarged Board of Appeal, it is a necessary and sufficient condition for a divisional application to comply with this provision that anything disclosed in that divisional application be directly and unambiguously derivable from what is disclosed in the earlier application as filed (see decision G 1/06, OJ EPO 2008, 307, Order).

5. Claim 1 is directed to antibodies defined inter alia by their ability to compete with a reference antibody for binding to a cell that expresses human IL-4 receptor. It was common ground that this ability was defined in the description of the earlier application as filed solely in respect of competition with antibodies designated "6-2" and "1B7" (see pages 24 and 28). The passage on page 24, reads "Particular monoclonal antibodies of the invention are selected from the group consisting of MAb 6-2; a Mab that is cross-reactive with 6-2; a MAb that binds to the same epitope as 6-2; a MAb that competes with 6-2 for binding to a cell that expresses human IL-4R; a MAb that possesses a biological activity of 6-2; and an antigen-binding fragment of any of the foregoing antibodies." (emphasis added by the board). The passage on page 28 reads similarly in respect of antibody 1B7.

6. Claim 1 recites the SEQ ID NOs 6 and 8, in part a), and SEQ ID NOs 26 and 24, in part b), which correspond to the sequences of the variable regions of the light and heavy chains of antibodies 6-2 and 1B7, respectively (see earlier application as filed on page 25, lines 35 to 38 and page 29 , lines 3 to 11, respectively).

7. The earlier application as filed does not disclose the specific sequences of the constant regions of the light and heavy chains of antibodies 6-2 and 1B7. The question in dispute between the parties was whether the absence of any constant region sequences from the claim led to a definition of the reference antibody which differed from antibodies 6-2 and 1B7 as disclosed in the above-mentioned pages 24 and 28 of the earlier application as filed.

8. Examples 4 and 6 of the earlier application describe the preparation of hybridomas and selection of a clone secreting the antibody 6-2. The same applies to example 9 with respect to antibody 1B7. Each hybridoma clone secretes only one specific (monoclonal) antibody and not a whole class of antibodies. The board concludes from this that the designations 6-2 and 1B7 denote specific monoclonal antibodies, entailing specific constant region sequences.

9. This view is supported by the passage of the earlier application describing the preparation of antibody 1B7 from antibody 63 and comparing their constant region sequences, as follows: "MAb 1B7 was derived from MAb 63. The amino acid sequence of the heavy chain of MAb 1B7 is identical to that of MAb 63." (see page 29, lines 3 to 5).

10. The fact that the sequences of the constant regions are not disclosed in the earlier application does not change the assessment that a specific full monoclonal antibody was meant by "6-2" and "1B7".

11. It follows from the above that the passages on pages 24 and 28 of the description define antibodies by reference to specific antibodies 6-2 and 1B7. However, the claim is directed to antibodies defined by reference to a generalisation of antibodies 6-2 and 1B7. The skilled person would not derive this definition directly and unambiguously from the earlier application as filed and accordingly the requirements of Article 76(1) EPC are not met.

12. Contrary to the appellant's argument, the board holds that the lack of full characterisation of antibodies 6-2 and 1B7 in the earlier application does not entitle the appellant to replace those specific monoclonal antibodies, for which there is disclosure in the context of competing antibodies, with a generalisation for which there is no basis in the earlier application as filed. In a case where the antibodies sought to be claimed cannot be defined by reference to competition with antibodies 6-2 and 1B7, which are internal designations in the case in hand, then an alternative definition must be pursued, relying on what was disclosed in the earlier application as filed.

13. Finally, the passage of the Guidelines for Examination at the EPO, G-II, 5.6.1.1, cited by the appellant, refers to the requirements of clarity (Guidelines for Examination, editions March 2021 and March 2022) and is therefore not pertinent to the issue at hand, which is the requirement that the divisional application be filed only in respect of subject-matter which does not extend beyond the content of the earlier application as filed.

14. Claim 1 of auxiliary request 1 also includes this definition of the antibodies. Therefore, the finding of lack of compliance with Article 76(1) EPC applies to both requests equally.

Auxiliary requests 2 and 3 - claim 1

Clarity (Article 84 EPC)

15. The feature "wherein the reference IgM antibody is generated in transgenic mouse strain ((CMD)++; (JKD)++; (HCo7)11952+/++; (KCo5)9272+/++)" was introduced into claim 1 of auxiliary request 2 during the proceedings before the opposition division. This feature is not included in any of the claims of the patent as granted. Rather it is based on a disclosure in the description (see paragraph [0246] of the patent). This amendment was therefore open to examination for compliance with the requirements of Article 84 EPC (see decision G 3/14, OJ EPO 2015, A102). This was not disputed by the appellant.

16. According to established case law of the boards of appeal of the EPO, the requirement for clarity of the claims in Article 84 EPC entails that the claims define and delimit the matter for which protection is sought in understandable and unambiguous terms. The claims must be clear in themselves when being read by the skilled person, including the knowledge about the prior art but not including any knowledge derived from the description of the patent application or the amended patent (see decisions cited in the Case Law of the Boards of Appeal of the European Patent Office, 9th edition, 2019, II.A.3.1, first paragraph).

17. In their replies to the statement of grounds of appeal, the respondents submitted that the feature referring to a transgenic mouse was not clear. The appellant presented several lines of argument to argue the clarity of the claim.

18. In a first line of argument, the appellant submitted that the terminology used in the claim to define the transgenic mouse was standard in the technical field and its meaning clear to the skilled person.

19. The appellant relied in this respect on document D154, whereas respondent I referred to documents D116, D117 and D132. These declarations make contradictory statements on this issue. In document D154, it is asserted that the terminology was generally accepted in the field and the meaning of the expression at issue was clear. However, there is no documentary evidence on file which allows the board to establish that the terminology in question belonged to the common general knowledge of the skilled person at the relevant date. The only document filed in this respect is document D131 which corresponds to the patent document cited in paragraph [0246] of the patent. It is a patent document and therefore the fact that it uses a certain terminology does not on its own establish that such terminology belonged to the common general knowledge of the skilled person. Although document D154 refers to four scientific publications, these have not been filed and are not part of these proceedings. Moreover, they are referred to solely in respect of disclosing the terminology "HC" and "KC" but not in respect of disclosing any of the other terms in the claim such as "HCo7" and "KCo5", addressed here below.

20. In a further line of argument, the appellant stated that the description provided an explanation of the terminology and contained references using that terminology. As regards specifically the meaning of HCo7 and KCo5, the appellant argued with reference to document D154 that the meaning would be known to the skilled person from paragraphs [0246] and [0247] of the patent and document D131 cited therein.

21. It was disputed by the respondents that the description of the patent could be taken into account for interpreting the claim. However, the board comes to the conclusion that, even when interpreting the claim in the light of the description, the sequence of transgenes HCo7 and KCo5 can nevertheless not be determined, even when further taking account of the contents of document D131. This is the case because neither the above-cited paragraphs of the description nor document D131 indicate the respective sequences of genes HCo7 and KCo5.

22. In document D154, examples 12, 21, 37 and 38 in document D131 are mentioned as disclosing how the transgenes were generated, namely that they were "obtained from a phage library containing human genomic DNA" (see page 6, first paragraph of document D154). This correct account of the disclosure of document D131 does not therefore indicate a passage in this, or any other document, which discloses the sequences of the genes. In fact, no such passage is present in document D131. This is consistent with the statements in declarations D116 (section F.) and D117 (section A)5.), filed by respondent I, pointing out that the sequences of the heavy and light chain constant regions were not known since their source was not identified other than by reference to a phage P1 library of unspecified origin (see example 37, as regards transgene HCo7) and a library of human placental DNA of unspecified origin (see example 38 in combination with example 21, as regards transgene KCo5). Indeed document D131 describes in example 37 the generation of transgenic mice with inactivated endogenous light and heavy chain loci and containing transgene HCo7 (see example 37, column 133, lines 55 to 59). Preparation of transgene HCo7 is described with reference to five clones and refers to screening of a phage P1 library (see example 37, column 135, lines 36 to 39 and column 137, lines 12 to 14). As regards the source of DNA material for gene KCo5, example 21 refers to a human placental DNA library to generate a KCo4 transgene. The KCo5 transgene used in example 38 is described as corresponding to the DNA in KCo4 with additional DNA segments (see example 38, column 143, lines 5 to 7 and example 21, column 101, lines 25 to 27). The appellant has not directed the board to other passages of this or other documents which specifically disclose the sequences and rebut such statements.

23. Consequently, claim 1 lacks clarity, contrary to the requirements of Article 84 EPC.

24. Claim 1 of auxiliary request 3 includes the feature discussed with respect to claim 1 of auxiliary request 2, except that the term "reference" has been deleted (see the claim wording in point X.). Thus, the considerations in points 15. to 23. above apply equally to this claim.

25. In view of the foregoing, none of the claim requests forming part of the appeal proceedings meets the requirements of the EPC. Accordingly, the patent cannot be maintained on the basis of any of these requests.

Order

For these reasons it is decided that:

The appeal is dismissed.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility